Dyne Therapeutics, Inc. Stock News

WALTHAM, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for pe

Dyne: H2 2024 Muscle Disease Data Could Boost Value

WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peop

While investors should probably direct the majority of their market-earmarked funds toward slow-and-steady ideas – à la Warren Buffett – sometimes, we end up with gambling money. And in that case

WALTHAM, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peop

Dyne Therapeutics is off to a strong start in 2024 with positive trial data from its Duchenne muscular dystrophy (DMD) program. The company released positive initial proof-of-concept data for its two

Dyne Therapeutics (NASDAQ: DYN ) stock is taking off on Wednesday after the muscle disease company announced positive clinical trial data. According to a press release from Dyne Therapeutics, its ACH

Dyne Therapeutics Inc. shares DYN, -1.80% jumped 40% premarket on Wednesday after the company released new data from trials of two investigational treatments for genetic muscle disorders. The experime

WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peop

After dropping to 52-week lows, the markets have been rallying lately. That has traders and investors scrambling for cheap stocks under $20 to buy.

WALTHAM, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peo

Dyne Therapeutics is a clinical-stage biotech. The company focuses on rare genetic disorders.

Dyne Therapeutics is developing treatments for genetically driven muscle diseases, focusing on Myotonic Dystrophy Type 1 (DM1) and Duchenne Muscular Dystrophy (DMD). Their lead candidate, DYNE-101, is

WALTHAM, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for peop

Dyne Therapeutics, Inc. has announced that its investigational therapeutic, DYNE-251, for Duchenne muscular dystrophy (DMD), has been granted FDA orphan drug and rare pediatric disease designations. D